Watch for completion of NDA submission by year-end 2026 and the PDUFA date of February 27, 2027 for the second-line monotherapy NDA. The first-line data from REZILIENT3 could support a broader label, significantly expanding the addressable patient population.
Price Chart
Executive Summary
Cullinan Therapeutics announced initiation of an NDA submission to the FDA for zipalertinib plus chemotherapy in first-line EGFR exon20ins NSCLC under the RTOR program, based on the Phase 3 REZILIENT3 trial that met its primary endpoint. The company is eligible for $30M and $100M milestone payments upon second-line and first-line U.S. regulatory approvals, respectively. This is a significant regulatory catalyst for a clinical-stage biotech with a first-in-class asset.
Key Financial Metrics
Key Facts
- NDA submission initiated under FDA's Real-Time Oncology Review (RTOR) program for zipalertinib plus chemotherapy in first-line EGFR exon20ins NSCLC.
- Phase 3 REZILIENT3 trial met primary endpoint with statistically significant and clinically meaningful improvement in median progression-free survival.
- Completion of NDA submission expected by year-end 2026.
- Cullinan eligible for $30 million milestone upon second-line U.S. regulatory approval and $100 million upon first-line U.S. regulatory approval.
- Zipalertinib holds FDA Breakthrough Therapy designation for previously treated EGFR ex20ins NSCLC.
- Separate NDA for accelerated approval of zipalertinib monotherapy in second-line setting has PDUFA target action date of February 27, 2027.
Financial Impact
Up to $130 million in milestone payments from partner Taiho upon U.S. regulatory approvals ($30M second-line, $100M first-line).
Risk Factors
- Regulatory approval is not guaranteed; the FDA may issue a Complete Response Letter (CRL) or require additional data.
- Competition from other EGFR exon20ins therapies (e.g., amivantamab, mobocertinib) may limit commercial uptake.
- Cullinan is a clinical-stage biotech with no approved products; reliance on partner Taiho for development and commercialization.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373489 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | Press Release | $15.51 | awaiting T+60 | — | $14.54 (−6.25%) |
Sep 24, 2026 4w ago | 8-K | $15.44 | awaiting T+60 | — | $14.54 (−5.83%) |
Sep 24, 2026 4w ago | Press Release | $15.44 | awaiting T+60 | — | $14.54 (−5.83%) |
Sep 22, 2026 4w ago | Institutional Cluster | $21.67 | awaiting T+60 | — | $14.54 (−32.90%) |
Sep 14, 2026 6w ago | 8-K | $20.40 | awaiting T+60 | — | $14.54 (−28.73%) |
Aug 6, 2026 11w ago | 8-K | $17.95 | awaiting T+60 | — | $14.54 (−19.00%) |
Jun 11, 2026 19w ago | Institutional Cluster | $12.98 $21.69 | ▲ +67.10% | ▲ +63.28% | $14.54 (+12.02%) |
Jun 10, 2026 19w ago | Press Release | $12.05 $22.09 | ▲ +83.32% | ▲ +77.15% | $14.54 (+20.66%) |
Jun 8, 2026 20w ago | 8-K | $13.28 $22.33 | ▲ +68.15% | ▲ +64.64% | $14.54 (+9.49%) |
May 19, 2026 22w ago | Press Release | $14.18 $19.64 | ▲ +38.55% | ▲ +32.26% | $14.54 (+2.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers